El Salvador vs Guyana: HIV/AIDS deaths averted by antiretroviral therapy
El Salvador
521.19 deaths
in 2024
Guyana
512.85 deaths
in 2024
El Salvador rank
90th
Guyana rank
93rd
HIV/AIDS deaths averted by antiretroviral therapy over time
- El Salvador
- Guyana
How they compare
El Salvador currently reports 521.19 deaths against 512.85 deaths in Guyana, a difference of 8.34 deaths.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Guyana ahead.
El Salvador ranks 90th and Guyana ranks 93rd of 157 countries.
El Salvador has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | El Salvador | Guyana | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 374.61 deaths | 139.91 deaths | 234.7 deaths | El Salvador |
| 2010s | 792.19 deaths | 424.71 deaths | 367.48 deaths | El Salvador |
| 2020s | 558.8 deaths | 494.78 deaths | 64.02 deaths | El Salvador |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, El Salvador or Guyana?
- El Salvador, at 521.19 deaths against 512.85 deaths in Guyana as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between El Salvador and Guyana?
- 8.34 deaths, with El Salvador ahead.
- How many years of comparable data are there for El Salvador and Guyana?
- 35 years are reported by both, from 1990 to 2024.
- How do El Salvador and Guyana rank globally for hiv/aids deaths averted by antiretroviral therapy?
- El Salvador ranks 90th and Guyana ranks 93rd of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.